Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease

开发针对严重遗传神经系统疾病的一流聚集特异性抗体

• 批准号: 10076445
• 金额: $ 6.35万
• 依托单位: GOM THERAPEUTICS LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10076445
• 关键词: Developing; first; class; aggregation; specific

GOM Therapeutics is developing a first-in-class therapeutic for a common genetic neurovascular disease with no existing treatment. The disease is a progressive, chronic adult-onset disorder that leads to dementia, physical disability and premature death. This heritable condition significantly affects the lives of patients and their families. We are taking a highly innovative approach, building on important recent scientific advances.Our project aims to assess the feasibility of making an important starting component for our drug discovery process. This project represents an important step in potentially bringing a novel therapy to an underserved group of patients.

GoM治疗公司正在开发一种一流的治疗方法，用于治疗一种常见的遗传性神经血管疾病，目前还没有治疗方法。这种疾病是一种进行性的、慢性成人发病的疾病，会导致痴呆症、身体残疾和过早死亡。这种可遗传的疾病严重影响了患者及其家人的生活。我们正在采取一种高度创新的方法，以最近的重要科学进步为基础。我们的项目旨在评估将其作为我们药物发现过程的重要起始组成部分的可行性。该项目代表着可能将一种新的治疗方法带给服务不足的患者群体的重要一步。